Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2025 results Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2025 results Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2025 results Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2025 results Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial in your area.
Oral Semaglutide Reduces CV Events in T2DM – SOUL Trial (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉
23.19
Trial Scorecard: SOUL
23.42
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
24.24
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
28.24
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
20.94
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
29.15
Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial
29.34
